Lunai Bioworks Inc. insider trading

Every open-market purchase and sale by Lunai Bioworks Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

No open-market insider trades reported in the last five years.

Does following Lunai Bioworks Inc.’s insiders pay?

From June 4, 2018 to July 19, 2024, 5 insiders reported 10 open-market purchases and 8 sales not made under a pre-set plan in Lunai Bioworks Inc. Twelve months after each purchase was reported, the shares were −48.4% against the S&P 500 on average (median −50.3%), over 10 purchases with a full year of prices; 10% beat the index. After sales, the shares moved −90.6% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on June 5, 2018 into $1,998 by November 2, 2026, −17.5% a year. It held shares 36% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $15,242 (+5.2% a year), and held throughout $31,275 (+14.6%).

Copying Lunai Bioworks Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Lunai Bioworks Inc.'s insiders from June 5, 2018, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 36% of the time.

Lunai Bioworks Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Sindlev Rene	Director	8	−52.6% (8)	0%	0	—	May 20, 2022
William Anderson Wittekind	10% owner	0	—	—	7	—	July 19, 2024
Gronfeldt-Sorensen Henrik	Director	1	−74.1% (1)	0%	0	—	January 11, 2019
Gumrukcu Serhat	10% owner	0	—	—	1	−90.6% (1)	May 20, 2022
Leire, Eric Jean Marie	Other	1	+11.6% (1)	100%	0	—	June 4, 2018

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Lunai Bioworks Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Lunai Bioworks Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −35.4% against the index. One company's history is too short to judge by; the test across every company is the better guide.

Month	Crowd	3 months on, vs S&P 500	6 months	12 months
January 31, 2019	2 buying	−13.4%	−35.4%	−53.1%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Lunai Bioworks Inc. · Funds · Politicians